Performance analysis of Neuphoria Therapeutics (NEUP)
Annual Return
Since Dec 23, 2024, NEUP has had an average annual return of -78.06%, underperforming the benchmark SPY, which returned +16.96% annual.
| 2026 | 2025 | 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.90% | +13.18% | -90.59% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.57% | +3.26% | -1.93% | +29.54% | +0.76% | -17.76% | -23.52% | -13.90% | |||||
| 2025 | +54.62% | -1.92% | +10.79% | -11.95% | +31.03% | +6.85% | +14.21% | +39.71% | +4.05% | -61.40% | -0.64% | -14.18% | +13.18% |
| 2024 | -90.59% | -90.59% |
Drawdown analysis of Neuphoria Therapeutics (NEUP)
The maximum drawdown for the NEUP was -96.32%, occurring on Jan 2, 2025. This drawdown has not yet recovered.
The current NEUP drawdown is -95.80%.
Since Dec 23, 2024 NEUP has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.32% | Dec 24, 2024 | 5 | Jan 2, 2025 | Ongoing | Ongoing | Ongoing |